/ /

ModernMedicine Resource Center More Topics

Uveitis Resource Center

5 intriguing ARVO abstracts about uveitisAt the 2016 Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, about 100 uveitis and uveitis-related papers and posters were presented by researchers from around the world. The presentations covered a wide range of research initiatives that are underway to treat–or at least understand how to address–uveitis. Here are five intriguing abstracts of research that were presented at the meeting.
Clinical pearls for treating uveitisUveitis presents particular problems for ophthalmologists. Inflammation inside the eye can occur from so many causes that the diagnosis often requires painstaking, time-consuming investigation. As researchers have learned more about the disease, the possible etiologies and treatments have multiplied.
7 common mistakes in managing uveitic glaucomaGlaucoma is a common complication of uveitis, occurring in about 20% of affected eyes and arising through several different mechanisms. Here are seven common mistakes clinicians make in evaluating and managing elevated IOP in eyes with uveitis.
Exploring balance of controlling inflammation, IOP in uveitisClinicians need to weigh such factors as inflammation and IOP in determining when steroid therapy is beneficial in uveitic glaucoma.
Positive results reported for anti-interleukin-6 agent for uveitisIntravenous administration of the anti-interleukin-6 (IL-6) agent tocilizumab (Actemra, Genentech) is well-tolerated in patients with non-infectious uveitis involving the posterior segment and showing promising efficacy, according to interim outcomes reported by Quan Dong Nguyen, MD.